Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | PSMA ADC in prostate cancer: Phase I results

Daniel Petrylak • 15 Feb 2019
GU Cancers 2019
Genitourinary Cancer Prostate Cancer

Prof. Daniel Petrylak, MD, from the Yale Cancer Center, New Haven, CT, presents results from a Phase I study, where chemotherapy-refractory prostate cancer patients were given prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in escalating doses. At the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Prof. Petrylak also speaks of the recently completed Phase II trial (NCT01695044), where patients with no prior chemotherapy were administered PSMA ADC, with the results still pending.

More from Daniel Petrylak

0:43
Current developments in FGFR inhibitors for urothelial cancer
Daniel Petrylak • 3 Jun 2023
1:59
How can we best sequence novel treatments in urothelial cancer?
Daniel Petrylak • 3 Jun 2023
0:24
HER2-targeting ADCs for urothelial carcinoma
Daniel Petrylak • 3 Jun 2023
1:04
THOR: erdafitinib in advanced or metastatic urothelial cancer and FGFR alterations
Daniel Petrylak • 3 Jun 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals